Literature DB >> 29758578

[CF Lung Disease - a German S3 Guideline: Module 2: Diagnostics and Treatment in Chronic Infection with Pseudomonas aeruginosa].

C Schwarz1, B Schulte-Hubbert2, J Bend3, M Abele-Horn4, I Baumann5, W Bremer6, F Brunsmann7, D Dieninghoff8, O Eickmeier9, H Ellemunter10, R Fischer11, J Grosse-Onnebrink12, J Hammermann13, H Hebestreit14, M Hogardt15, C Hügel16, M Hug17, S Illing18, A Jung19, B Kahl20, A Koitschev21, R Mahlberg22, J G Mainz23, F Mattner24, A Mehl1, A Möller25, C Muche-Borowski26, T Nüßlein27, M Puderbach28, S Renner29, E Rietschel30, F C Ringshausen31, S Schmidt32, L Sedlacek33, H Sitter34, C Smaczny16, B Tümmler35, R Vonberg33, M O Wielpütz36, H Wilkens37, B Wollschläger38, J Zerlik39, U Düesberg3, S van Koningsbruggen-Rietschel30.   

Abstract

Cystic Fibrosis (CF) is the most common autosomal-recessive genetic disease affecting approximately 8000 people in Germany. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the epithelial lining fluid which leads to chronic inflammation of the airways. Recurrent infections of the airways as well as pulmonary exacerbations aggravate chronic inflammation, lead to pulmonary fibrosis and tissue destruction up to global respiratory insufficiency, which is responsible for the mortality in over 90 % of patients. The main aim of pulmonary treatment in CF is to reduce pulmonary inflammation and chronic infection. Pseudomonas aeruginosa (Pa) is the most relevant pathogen in the course of CF lung disease. Colonization and chronic infection are leading to additional loss of pulmonary function. There are many possibilities to treat Pa-infection. This is a S3-clinical guideline which implements a definition for chronic Pa-infection and demonstrates evidence-based diagnostic methods and medical treatment for Pa-infection in order to give guidance for individual treatment options. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29758578     DOI: 10.1055/s-0044-100191

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  3 in total

Review 1.  [Evidence-based treatment of cystic fibrosis].

Authors:  F C Ringshausen; T Hellmuth; A-M Dittrich
Journal:  Internist (Berl)       Date:  2020-12       Impact factor: 0.743

2.  Pharmacokinetics of Meropenem in People with Cystic Fibrosis-A Proof of Concept Clinical Trial.

Authors:  Jan C Kamp; Jan Fuge; Felix C Ringshausen; Denis Grote-Koska; Korbinian Brand; Lukas Graalmann; Ralf-Peter Vonberg; Tobias Welte; Jessica Rademacher
Journal:  Antibiotics (Basel)       Date:  2021-03-11

Review 3.  [Management of Primary Ciliary Dyskinesia].

Authors:  J Raidt; J Brillault; F Brinkmann; A Jung; C Koerner-Rettberg; A Koitschev; H Linz-Keul; T Nüßlein; F C Ringshausen; J Röhmel; M Rosewich; C Werner; H Omran
Journal:  Pneumologie       Date:  2020-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.